Literature DB >> 3257660

Evaluation of the S-type of alpha-1-antitrypsin as an in vivo and in vitro inhibitor of neutrophil elastase.

F Ogushi1, R C Hubbard, G A Fells, M A Casolaro, D T Curiel, M L Brantly, R G Crystal.   

Abstract

S-type alpha 1-antitrypsin (alpha 1AT) is a deficiency haplotype that differs from the common normal M1 (val213) alpha 1AT haplotype by a single amino acid (glu264 to val264). To evaluate the adequacy of the antineutrophil elastase protection associated with the S homozygous state, alpha 1AT plasma and lung epithelial lining fluid (ELF) levels and antineutrophil elastase function were analyzed in 9 PISS subjects. The plasma alpha 1AT levels of SS subjects were intermediate between that of M1M1 and ZZ subjects (p less than 0.001, all comparisons) and the plasma neutrophil elastase inhibitory capacity paralleled the differences in alpha 1AT concentration (p less than 0.001, all comparisons). The association rate constant for neutrophil elastase of the purified S protein was less than that of the normal molecule (S-type, 7.1 +/- 0.1 X 10(6) M-1 s-1; M1-type, 9.6 +/- 0.2 X 10(6) M-1 s-1; p less than 0.001), but much greater than that for the Z molecule (p less than 0.001). Exposure of the purified S protein to increasing oxidant burdens resulted in a dose-dependent reduction in the ability of the molecule to inhibit neutrophil elastase in a fashion parallel to that of the M1 and Z proteins. Quantification of ELF alpha 1AT levels and antineutrophil elastase capacity demonstrated that the SS ELF parameters were, as in plasma, intermediate between M1 homozygotes and Z homozygotes. Using the association rate constant together with the quantification of ELF alpha 1AT levels, the "in vivo lung inhibition time" was estimated, yielding an assessment of the relative antineutrophil elastase screen of the PISS lower respiratory tract.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3257660     DOI: 10.1164/ajrccm/137.2.364

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  Molecular multitasking in the airspace: alpha1-antitrypsin takes on thrombin and plasmin.

Authors:  Rubin M Tuder; Irina Petrache
Journal:  Am J Respir Cell Mol Biol       Date:  2007-05-31       Impact factor: 6.914

2.  Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease.

Authors:  Katie M Stiles; Dolan Sondhi; Stephen M Kaminsky; Bishnu P De; Jonathan B Rosenberg; Ronald G Crystal
Journal:  Chronic Obstr Pulm Dis       Date:  2018-08-17

Review 3.  Gene Therapy for Alpha-1 Antitrypsin Deficiency Lung Disease.

Authors:  Maria J Chiuchiolo; Ronald G Crystal
Journal:  Ann Am Thorac Soc       Date:  2016-08

4.  Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy.

Authors:  Mark L Brantly; Jeffrey D Chulay; Lili Wang; Christian Mueller; Margaret Humphries; L Terry Spencer; Farshid Rouhani; Thomas J Conlon; Roberto Calcedo; Michael R Betts; Carolyn Spencer; Barry J Byrne; James M Wilson; Terence R Flotte
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-12       Impact factor: 11.205

5.  Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.

Authors:  Alessandro N Franciosi; Brian D Hobbs; Oliver J McElvaney; Kevin Molloy; Craig Hersh; Louise Clarke; Cedric Gunaratnam; Edwin K Silverman; Tomás P Carroll; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

6.  Alpha1-antitrypsin inhibits the activity of the matriptase catalytic domain in vitro.

Authors:  Sabina Janciauskiene; Izabela Nita; Devipriya Subramaniyam; Qian Li; Jack R Lancaster; Sadis Matalon
Journal:  Am J Respir Cell Mol Biol       Date:  2008-08-21       Impact factor: 6.914

7.  Recombinant DNA-produced alpha 1-antitrypsin administered by aerosol augments lower respiratory tract antineutrophil elastase defenses in individuals with alpha 1-antitrypsin deficiency.

Authors:  R C Hubbard; N G McElvaney; S E Sellers; J T Healy; D B Czerski; R G Crystal
Journal:  J Clin Invest       Date:  1989-10       Impact factor: 14.808

8.  α-1-antitrypsin variants and the proteinase/antiproteinase imbalance in chronic obstructive pulmonary disease.

Authors:  Nicola J Sinden; Michael J Baker; David J Smith; Jan-Ulrich Kreft; Timothy R Dafforn; Robert A Stockley
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2015-01-15       Impact factor: 5.464

9.  Deficient and Null Variants of SERPINA1 Are Proteotoxic in a Caenorhabditis elegans Model of α1-Antitrypsin Deficiency.

Authors:  Erin E Cummings; Linda P O'Reilly; Dale E King; Richard M Silverman; Mark T Miedel; Cliff J Luke; David H Perlmutter; Gary A Silverman; Stephen C Pak
Journal:  PLoS One       Date:  2015-10-29       Impact factor: 3.240

10.  Alpha-1 antitrypsin Pi*SZ genotype: estimated prevalence and number of SZ subjects worldwide.

Authors:  Ignacio Blanco; Patricia Bueno; Isidro Diego; Sergio Pérez-Holanda; Beatriz Lara; Francisco Casas-Maldonado; Cristina Esquinas; Marc Miravitlles
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-08
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.